JP7626416B2 - 神経変性疾患または神経炎症性疾患におけるグリア細胞活性化の早期検出方法 - Google Patents
神経変性疾患または神経炎症性疾患におけるグリア細胞活性化の早期検出方法 Download PDFInfo
- Publication number
- JP7626416B2 JP7626416B2 JP2019566047A JP2019566047A JP7626416B2 JP 7626416 B2 JP7626416 B2 JP 7626416B2 JP 2019566047 A JP2019566047 A JP 2019566047A JP 2019566047 A JP2019566047 A JP 2019566047A JP 7626416 B2 JP7626416 B2 JP 7626416B2
- Authority
- JP
- Japan
- Prior art keywords
- sema4d
- pharmaceutical composition
- seq
- antagonist antibody
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762461945P | 2017-02-22 | 2017-02-22 | |
| US62/461,945 | 2017-02-22 | ||
| PCT/US2018/018794 WO2018156509A1 (en) | 2017-02-22 | 2018-02-20 | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020510845A JP2020510845A (ja) | 2020-04-09 |
| JP2020510845A5 JP2020510845A5 (cg-RX-API-DMAC7.html) | 2021-03-25 |
| JP7626416B2 true JP7626416B2 (ja) | 2025-02-04 |
Family
ID=63253999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019566047A Active JP7626416B2 (ja) | 2017-02-22 | 2018-02-20 | 神経変性疾患または神経炎症性疾患におけるグリア細胞活性化の早期検出方法 |
Country Status (14)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2427212B1 (en) | 2009-05-08 | 2017-08-23 | Vaccinex, Inc. | Anti-cd100 antibodies and methods for using the same |
| EA029023B1 (ru) | 2011-10-11 | 2018-01-31 | Вэксинекс, Инк. | Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) * | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| US9243068B2 (en) | 2013-06-25 | 2016-01-26 | Vaccinex, Inc. | Combination of SEMA-4D inhibitors and immunomodulators to inhibit tumors and metastases |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| PT3445397T (pt) | 2016-04-22 | 2023-01-13 | Vaccinex Inc | Exibição de proteína integral de membrana sobre viriões envelopados extracelulares de poxvírus |
| SG11201900595YA (en) | 2016-08-02 | 2019-02-27 | Vaccinex Inc | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
| JP7246320B2 (ja) | 2017-05-05 | 2023-03-27 | バクシネックス インコーポレーティッド | ヒト抗セマフォリン4d抗体 |
| US11597765B2 (en) | 2020-06-25 | 2023-03-07 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules for the treatment of Rett syndrome |
| MX2024003883A (es) * | 2021-09-27 | 2024-08-28 | Vaccinex Inc | Perfil predictivo de resultados para el uso de una molecula de union de antisemaforina-4d para el tratamiento de trastornos neurodegenerativos. |
| EP4692124A1 (en) * | 2023-04-03 | 2026-02-11 | Sialbio Co., Ltd. | Pharmaceutical composition for preventing or treating sjogren's syndrome, containing recombinant anti-semaphorin 4d antibody as active ingredient |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017502920A (ja) | 2013-10-21 | 2017-01-26 | バクシネックス インコーポレーティッド | 神経変性障害の処置のためのセマフォリン−4d結合分子の使用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0892047A3 (de) * | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Humanes und murines Semaphorin L |
| CN102089430B (zh) * | 2008-05-09 | 2015-02-04 | Abbvie公司 | 针对渐进性糖化终极产物受体(rage)的抗体及其用途 |
| EA029023B1 (ru) * | 2011-10-11 | 2018-01-31 | Вэксинекс, Инк. | Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера |
| US10494440B2 (en) * | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| NZ630881A (en) * | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| WO2017011746A1 (en) * | 2015-07-15 | 2017-01-19 | Adm Diagnostics, Llc | System and methods for determining a brain condition of a patient sybject to multiple disease states |
-
2018
- 2018-02-20 KR KR1020197027287A patent/KR102533921B1/ko active Active
- 2018-02-20 MX MX2019009986A patent/MX2019009986A/es unknown
- 2018-02-20 RU RU2019122337A patent/RU2766341C2/ru active
- 2018-02-20 IL IL267940A patent/IL267940B2/en unknown
- 2018-02-20 JP JP2019566047A patent/JP7626416B2/ja active Active
- 2018-02-20 CN CN201880013208.3A patent/CN110325213A/zh active Pending
- 2018-02-20 AU AU2018225493A patent/AU2018225493B2/en active Active
- 2018-02-20 EP EP18757318.3A patent/EP3585435A4/en active Pending
- 2018-02-20 BR BR112019017367-6A patent/BR112019017367A2/pt unknown
- 2018-02-20 CA CA3050328A patent/CA3050328A1/en active Pending
- 2018-02-20 SG SG11201906670PA patent/SG11201906670PA/en unknown
- 2018-02-20 US US16/488,123 patent/US20190383836A1/en not_active Abandoned
- 2018-02-20 WO PCT/US2018/018794 patent/WO2018156509A1/en not_active Ceased
-
2019
- 2019-07-05 ZA ZA2019/04431A patent/ZA201904431B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017502920A (ja) | 2013-10-21 | 2017-01-26 | バクシネックス インコーポレーティッド | 神経変性障害の処置のためのセマフォリン−4d結合分子の使用 |
Non-Patent Citations (2)
| Title |
|---|
| University of Trento Centre for Computational and Systems Biology,No.TR-07-2007,〈URL:http://eprints.biblio.unitn.it/1711/1/TR-07-2007.pdf〉[2020年1月28日検索] |
| 脳循環代謝,2015年,Vol.26,pp.67-75 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110325213A (zh) | 2019-10-11 |
| IL267940B2 (en) | 2025-04-01 |
| RU2019122337A3 (cg-RX-API-DMAC7.html) | 2021-06-09 |
| SG11201906670PA (en) | 2019-08-27 |
| WO2018156509A1 (en) | 2018-08-30 |
| AU2018225493B2 (en) | 2025-03-06 |
| ZA201904431B (en) | 2024-11-27 |
| IL267940A (en) | 2019-09-26 |
| MX2019009986A (es) | 2019-10-14 |
| BR112019017367A2 (pt) | 2020-04-14 |
| IL267940B1 (en) | 2024-12-01 |
| JP2020510845A (ja) | 2020-04-09 |
| KR20190120784A (ko) | 2019-10-24 |
| AU2018225493A1 (en) | 2019-08-01 |
| RU2019122337A (ru) | 2021-03-23 |
| KR102533921B1 (ko) | 2023-05-17 |
| CA3050328A1 (en) | 2018-08-30 |
| RU2766341C2 (ru) | 2022-03-15 |
| EP3585435A4 (en) | 2020-12-16 |
| NZ755446A (en) | 2025-06-27 |
| EP3585435A1 (en) | 2020-01-01 |
| US20190383836A1 (en) | 2019-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102533921B1 (ko) | 신경변성 또는 신경염증성 질환에서의 신경교세포 활성화의 조기 검출 | |
| AU2021202095B2 (en) | Use of semaphorin-4D binding molecules for treating neurodegenerative disorders | |
| KR102036938B1 (ko) | 뇌에서 상승된 수준의 α-시누클레인을 진단하기 위한 항-α-시누클레인 항체의 용도 | |
| JP2024535403A (ja) | 神経変性障害を処置するための抗セマフォリン4d結合分子の使用に関する予測アウトカムプロファイリング | |
| EA044133B1 (ru) | Способ лечения симптомов ранней стадии болезни альцгеймера у субъекта |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210209 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210209 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20210514 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220202 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220825 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20221216 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20221216 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20230724 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241024 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20241024 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250116 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7626416 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |